REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
The benefits of Pluvicto include delaying tumor growth, extending life by about 20 months, and destroying tumor cells by damaging the DNA inside those cells. Xofigo, a radioligand therapy that was FDA approved in 2013, uses radium-223 dichloride as the radioisotope, but its ligand varies from Pluvicto. Pluvicto only attacks cancer cells expressing PSMA, but Xofigo attacks all bone metastases. Qualified patients are 30% less likely to die when treated by Xofigo than if treated by a placebo. Ra-223-chloride is an alpha-emitting bone targeting agent.
All records, in any form (including, but not limited to, written, electronic, magnetic, and optical records; and scans, x-rays, and electrocardiograms) that describe or record the methods, conduct, and/or results of a trial, the factors affecting a trial, and the actions taken. (ICH E6) Dose
It was announced in March 2017 that Galloway was standing as an independent candidate at the Manchester Gorton by-election, following the death of Sir Gerald Kaufman. Gorton had been one of Labour's safest seats. The by-election was cancelled following the announcement of the 2017 snap general election being held on 8 June. Galloway transferred his candidacy to the general election. Labour easily retained the seat; Galloway came a distant third with 6% of the vote. In the 2019 general election, Galloway contested the Parliamentary seat of West Bromwich East as an independent, describing himself as supportive of Corbyn's leadership and Brexit. He came sixth with 489 votes. On 14 December 2019, Galloway launched the Workers Party of Britain, which describes itself as "economically radical with an independent foreign policy" and "unequivocally committed to class politics". Galloway is the party's leader. In 2020 Galloway announced his intention to stand in an expected by-election in Rutherglen and Hamilton West, after sitting MP Margaret Ferrier breached COVID regulations, but the by-election was not held for 3 years. Galloway led All for Unity in the 2021 Scottish Parliament election and announced his intention to vote for the Conservative Party on the constituency vote, and for his party on the list vote. This contradicted other occasions when he said voting Conservative was something he would never consider. All for Unity received 23,299 votes in the election, or 0.9%, placing the party 7th nationally, with no seats.
Gutter oil, trench oil, sewer oil, hogwash oil and tainted oil (Chinese: 地沟油 / 地溝油; pinyin: dìgōu yóu, or 餿水油; sōushuǐ yóu) are Chinese slang terms primarily used in China and Taiwan to refer to recycled oil. It can be used to describe the illicit practice of restaurants reusing cooking oil that has already been cooked for longer than safety codes permit. It can also be used to describe the reprocessing of yellow grease collected from sources such as restaurant fryers, kitchen waste, slaughterhouse waste and sewer drains. Since 2011, the Chinese government has significantly cracked down on the reuse of gutter oil for human consumption, with the Chinese government also implementing clearer regulations for dealing with waste oil. Selling gutter oil in China can result in lengthy prison sentences or the death sentence with reprieve. For example, in 2014, businessman Zhu Chuanfeng was sentenced to the latter for selling gutter oil. That same year, a major gutter oil scandal was uncovered in Taiwan. In 2015, Yeh Wen-hsiang, who was the chairman of a Taiwanese food company, was sentenced to 22 years imprisonment and fined NT$50 million (US$1.6 million) for selling 243 tonnes of gutter oil.
Sources: en.wikipedia.org
Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for vitamins and minerals, PRIs for the European Union (same concept as RDAs), followed by what three government organizations deem to be the safe upper intake. RDAs are set higher than EARs to cover people with higher-than-average needs. Adequate Intakes (AIs) are set when there is insufficient information to establish EARs and RDAs. Countries establish tolerable upper intake levels, also referred to as upper limits (ULs), based on amounts that cause adverse effects. Governments are slow to revise information of this nature. For the U.S. values, except calcium and vitamin D, all data date from 1997 to 2004.
==== Assessments ==== Heseltine was not popular with his ministerial peers at this time. A story was told of how ministers had volunteered him to be the one "taken hostage by terrorists" in a mooted training exercise. Nonetheless, Heseltine emerged from the Heath government with an enhanced reputation. He had avoided the worst crises of that government: the two miners' strikes, incomes policy, industrial relations policy and Northern Ireland, as well as any direct involvement in British entry into the EEC. Heseltine's career under Heath's ministry saw him associated with local government reorganisation, prestige projects, Europe and state aid to industries, themes which would recur throughout his career. He had attained a higher public profile than many Cabinet ministers, and by 1974 he was being seriously tipped as a future prime minister. Heseltine was promoted to the Shadow Cabinet in June 1974 as Industry spokesman. If the Conservatives had won either of the general elections in 1974 (February or October) he would almost certainly have joined the Cabinet. He was shadowing Tony Benn, who planned a major expansion of public ownership through the National Enterprise Board. In the summer of 1974, Heseltine put together a team of over 20 Conservative MPs, each a specialist in a particular industry, to campaign against Benn's plans.
Deregulated kinase activity is a frequent cause of disease, in particular cancer, wherein kinases regulate many aspects that control cell growth, movement and death. Drugs that inhibit specific kinases are being developed to treat several diseases, and some are currently in clinical use, including Gleevec (imatinib) and Iressa (gefitinib).
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.